Sarcopenia triples dysphagia odds across cancers, meta-analysis findsMuscle Loss Linked to Swallowing Problems in Cancer Patients

This meta-analysis pooled data from 2,889 patients with cancer, including head and neck cancer, to evaluate the association between tumor-associated sarcopenia and dysphagia. The primary outcome was dysphagia, and the analysis found a significant positive association: sarcopenia was associated with more than double the odds of dysphagia (OR = 2.82, 95% CI 1.94 to 4.29, P < 0.001). Notably, effect sizes were similar between head and neck cancer and other tumor types (P = 0.9479), suggesting that sarcopenia is a universal risk factor across cancers.

The authors also investigated sources of heterogeneity. Sarcopenia assessment methods independently explained heterogeneity (P = 0.022), as did dysphagia assessment tools (P = 0.018). This indicates that the way sarcopenia and dysphagia are measured may influence the strength of the observed association.

Limitations include minor publication bias (P = 0.55). The authors emphasize that the association is not causal. They suggest that routine screening for sarcopenia and targeted interventions may reduce dysphagia risk and improve quality of life, but this recommendation is based on the association, not on interventional evidence.

For clinicians, this meta-analysis highlights sarcopenia as a potentially modifiable risk factor for dysphagia in cancer patients, regardless of tumor site. However, given the observational nature and heterogeneity in assessment methods, these findings should be interpreted cautiously and not as proof that treating sarcopenia will prevent dysphagia.